# Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

> **NCT05812430** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Biliary Tract Cancer

## Interventions

- **DRUG:** anlotinib+TQB2450+nab-paclitaxel+cisplatin

## Key facts

- **NCT ID:** NCT05812430
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-10
- **Primary completion:** 2023-10-10
- **Final completion:** 2024-10-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05812430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05812430, "Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05812430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*